Here at the Janssen Health Policy Centre
our mission is to raise awareness on issues impacting healthcare policy, build
consensus through dialogue, and shape recommendations for future policies
While innovation is central for the quality of healthcare and improving health outcomes, it is also a source of increasing costs for governments. Confronted by fiscal pressures, governments have made efforts to restrict access to innovative treatments. While such policies are understandable, they are not necessarily supportive of the ambition to control the cost burden of a disease. This paper reviews economic analyses of the cost burden of cancer, and blood cancers in particular, and the effects that innovative treatments have on other sources of costs in the healthcare system or the economy as a whole.
Janssen recently sponsored the European Centre for International Political Economy (ECIPE) summit.